• Home
  • Contact Us
  • Privacy & Policy
Saturday, May 21, 2022
Finances Advise
No Result
View All Result
  • Home
  • Business
  • Commodities
  • Crypto News
    • Block chain
    • Bitcoin
    • Ethereum
    • Litecoin
  • Finance
    • Financial Advisors
    • Personal Finance
    • Market Insider
  • Forex
  • Investing
  • Stocks
  • ICOs
  • Trading
  • Home
  • Business
  • Commodities
  • Crypto News
    • Block chain
    • Bitcoin
    • Ethereum
    • Litecoin
  • Finance
    • Financial Advisors
    • Personal Finance
    • Market Insider
  • Forex
  • Investing
  • Stocks
  • ICOs
  • Trading
No Result
View All Result
Finances Advise
No Result
View All Result
Home Business

AstraZeneca revises Covid vaccine data with lower efficacy rate after accuracy questions

by admin
March 25, 2021
in Business
0
152
SHARES
1.9k
VIEWS
Share on FacebookShare on Twitter


A healthcare worker prepares to inject an AstraZeneca coronavirus disease (COVID-19) vaccine.

Eloisa Lopez

AstraZeneca issued updated phase three trial data for its Covid-19 vaccine on Wednesday after facing accuracy questions earlier this week surrounding a preliminary report from its U.S. study.

The company now says its vaccine is 76% effective in protecting against symptomatic cases of virus. A release issued on Monday reported a symptomatic efficacy rate of 79%. The updated report maintains that the shot is 100% effective against severe disease and hospitalization.

A slate of U.S. health officials criticized the company in recent days for what some claimed was data cherry-picking in an effort to make the results appear more favorable.

The National Institute of Allergy and Infectious Diseases revealed on Tuesday it had been informed the U.K.-based company may have included information from its U.S. results that provided an “incomplete view of the efficacy data.”

AstraZeneca said at the time the figures were based on a “pre-specified interim analysis” and vowed to share updated analysis in the coming days.

Dr. Anthony Fauci, White House chief medical advisor and director at the NIAID, called the situation “unfortunate” and said it was likely AstraZeneca would issue a modified statement.

“This is really what you call an unforced error because the fact is this is very likely a very good vaccine,” Fauci told ABC’s Robin Roberts on “Good Morning America” on Tuesday. “This kind of thing does … really cast some doubt about the vaccines and maybe contribute to the hesitancy. It was not necessary.”

The updated results include data collected from 190 symptomatic cases, across more than 32,000 participants — an increase of roughly 50 symptomatic cases studied compared with the data set released on Monday.

The findings suggest the vaccine is more effective in patients aged 65 and older than previously understood, with a newly reported efficacy rate of 85% for that population, up from a previously stated 80%.

AstraZeneca reiterated Wednesday that the vaccine was “well tolerated” among participants and that no safety concerns were identified.

AstraZeneca faced a separate backlash in recent weeks over reports of blood clotting in conjunction with its vaccine, which is already approved and in use by dozens of countries around the world. Several European nations suspended, then resumed, use of the vaccine after independent safety reviews.

—CNBC’s Berkeley Lovelace Jr., Sam Meredith and Steve Kopack contributed to this report.

Tags: accuracyAstraZenecaCoviddataefficacyquestionsRaterevisesvaccine
  • Trending
  • Comments
  • Latest

A 48-year market vet warns that the Fed will be forced to tighten policy ‘way sooner’ than investors anticipate as inflation continues to soar — triggering a stock market crash of up to 80%

August 28, 2021
27-year-old UG graduate now millionaire proposes to girlfriend on b’day in video

27-year-old UG graduate now millionaire proposes to girlfriend on b’day in video

August 9, 2021

‘It’s begging to be destroyed’: A stock trader who says he made more than $100,000 shorting the market during the 2008 crash just bet against the S&P 500 — and warns there’s a ‘fair chance’ stocks are about to drop 25%

September 11, 2021

Stocks tanked in the first quarter, and new research shows there should be a reversal by the end of June

April 15, 2022
Will the Gold Rally Extend? – Action Forex

Will the Gold Rally Extend? – Action Forex

0

Uber Hacking: Customers Not at Risk of Financial Crime, Says Minister

0

Black Friday Merchants Look to Extend Moment of Retail Optimism

0

Hotshot Snapchat Founders Face a Dilemma: Lie Low or Live Large?

0
Will the Gold Rally Extend? – Action Forex

Will the Gold Rally Extend? – Action Forex

May 21, 2022

Biden bunko blows up with stock market

May 21, 2022
The Weekly Bottom Line: Energy Prices Eat into Buying Power – Action Forex

The Weekly Bottom Line: Energy Prices Eat into Buying Power – Action Forex

May 21, 2022

Stocks Have Been Falling. I’m Still Buying Steadily.

May 21, 2022

Recent News

Will the Gold Rally Extend? – Action Forex

Will the Gold Rally Extend? – Action Forex

May 21, 2022

Biden bunko blows up with stock market

May 21, 2022

Categories

  • Bitcoin
  • Block chain
  • Business
  • Commodities
  • Ethereum
  • Financial Advisors
  • Forex
  • Investing
  • Litecoin
  • Market Insider
  • Personal Finance
  • Stocks

Site Navigation

  • Home
  • Contact Us
  • Privacy & Policy

We bring the Best and latest Crypto News

© 2022 JNews - Premium WordPress news & magazine theme by Jegtheme.

No Result
View All Result
  • Home
  • Business
  • Commodities
  • Crypto News
    • Block chain
    • Bitcoin
    • Ethereum
    • Litecoin
  • Finance
    • Financial Advisors
    • Personal Finance
    • Market Insider
  • Forex
  • Investing
  • Stocks
  • ICOs
  • Trading

© 2022 JNews - Premium WordPress news & magazine theme by Jegtheme.